| 1 |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018, 68(6): 394-424.
|
| 2 |
Mizrahi JD, Surana R, Value JW, et al. Pancreatic cancer [J]. Lancet (London, England), 2020, 395(10242): 2008-2020.
|
| 3 |
Xu XH, Zeng XY, Wang LJ, et al. The disease burden of pancreatic cancer in China in 1990 and 2017[J]. Zhonghua liu xing bing xue za zhi ＝ Zhonghua liuxingbingxue zazhi, 2019, 40(9): 1084-1088.
|
| 4 |
刘荣，刘渠，王子政. 恶性肿瘤多元饱和治疗理念的探索[J/CD] 中华腔镜外科杂志(电子版)，2020, 13(3): 129-131.
|
| 5 |
Conroy T, Desseigne F, Ychou M, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer [J]. N Engl J Med, 2011, 364(19): 1817-1825.
|
| 6 |
Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine [J]. N Engl J Med, 2013, 369(18): 1691-703.
|
| 7 |
Paola Martinelli, Enrique Carrillo-de Santa Pau, Trevor Cox, et al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer [J]. Gut, 2017, 66(9): 1665-1676.
|
| 8 |
Andrea Wang-Gillam, Chung-Pin Li, György Bodoky, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial [J]. The Lancet, 2016, 387(10018): 545-557.
|
| 9 |
Jameson GS, Borazanci E, Babiker HM, et al. Response rate following albumin-bound paclitaxel plus gemcitabine plus cisplatin treatment among patients with advanced pancreatic cancer: a phase Ⅰb/2 pilot clinical trial [J]. JAMA Oncol, 2019, 6(1): 368-368.
|
| 10 |
Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial [J]. The Lancet Oncology, 2020, 21(4): 508-518.
|
| 11 |
Buscail L, Bournet B, Cordelier P. Role of oncogenic kras in the diagnosis, prognosis and treatment of pancreatic cancer [J]. Nature Reviews Gastroenterology & Hepatology, 2020, 17(3): 153-168.
|
| 12 |
Schultheis B, Reuter D, Ebert MP, et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in kras wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase Ⅱb study [J]. Ann Oncol, 2017, 28(10): 2429-2435.
|
| 13 |
Aguirre AJ, Nowak JA, Camarda ND, et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine [J]. Cancer Discov, 2018, 8(9): 1096-1111.
|
| 14 |
Nevala-plagemann C, Hidalgo M, Garrido-laguna I. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer[J]. Nat Rev Clin Oncol, 2020, 17(2): 108-123.
|
| 15 |
Schizas D, Charalampakis N, Kole C, et al. Immunotherapy for pancreatic cancer: a 2020 update [J]. Cancer Treat Rev, 2020. DOI: 10.1016/j.ctrv.2020.102016. |
| 16 |
Weiss GJ, Blaydorn L, Beck J, et al. Phase Ⅰb/Ⅱ study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma [J]. Invest New Drugs, 2018, 36(1): 96-102.
|
| 17 |
Bear AS, Vonderheide RH, O′hara MH. Challenges and opportunities for pancreatic cancer immunotherapy [J]. Cancer Cell, 2020, 38(6): 788-802.
|
| 18 |
Barcellini A, Peloso A, Pugliese L, et al. Locally advanced pancreatic ductal adenocarcinoma: challenges and progress [J]. Onco Targets Ther, 2020, 13: 12705-12720. DOI: 10.2147/OTT.S220971. |
| 19 |
Gemenetzis G, Groot VP, Blair AB, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection [J]. Ann Surg, 2019, 270(2): 340-347.
|
| 20 |
Yu X, Gu J, Fu D, et al. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma: a systematic review and meta-analysis [J]. International journal of surgery (London, England), 2017, 48: 149-154. DOI: 10.1016/j.ijsu.2017.10.066. |
| 21 |
De Simoni O, Scarpa M, Tonello M, et al. Oligometastatic pancreatic cancer to the liver in the era of neoadjuvant chemotherapy: which role for conversion surgery.a systematic review and meta-analysis [J]. Cancers (Basel), 2020.DOI: 10.3390/cancers12113402. |
| 22 |
严律南，杨家印．人工智能肝癌临床决策支持系统的开发，验证和应用价值[J]．中国普外基础与临床杂志，2020, 27(9)：10-14.
|
| 23 |
Corral JE, Hussein S, Kandel P, et al. Deep learning to classify intraductal papillary mucinous neoplasms using magnetic resonance imaging[J]. Pancreas, 2019, 48(6): 805-810.
|
| 24 |
Muhammad W, Hart GR, Nartowt B, et al. Pancreatic cancer prediction through an artificial neural network [J]. Frontiers in Artificial Intelligence, 2019. DOI: 10.3389/frai.2019.00002. |